Navigation Links
United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders
Date:5/1/2008

Annual Meeting of Shareholders to be Reconvened on May 29, 2008

SILVER SPRING, Md., May 1 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) (the Company) held its annual meeting of shareholders (the Annual Meeting) on April 29, 2008. The Company's shareholders voted to approve the election of Raymond Dwek, Roger Jeffs and Christopher Patusky as Class III directors with terms expiring in 2011. The Company's shareholders also voted to approve the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2008.

Following these votes, the Annual Meeting was adjourned and will be reconvened on May 29, 2008 to consider one remaining item of business: the adoption of the 2008 United Therapeutics Corporation Equity Incentive Plan (the 2008 Plan). The meeting was adjourned in order to allow shareholders time to consider a proposed amendment to the 2008 Plan (as so amended and restated, the Amended 2008 Plan).

The amendments reflected in the Amended 2008 Plan as compared with the original plan are summarized as follows:

Amendments Proposed Under the Amended Under the Original

2008 Plan 2008 Plan

Shares of common stock reserved

for grants 1,500,000 7,000,000

Final date for granting awards December 31, 2011 10 years after

shareholder approval

The ability to buy back awards Requires Allowed

or exchange them for other shareholder

consideration approval

The ability to lower the Requires Allowed

exercise price of any stock shareholder

option (other than in connection approval

with a change in our

capitalization)

Vesting of restricted stock - At least three Vesting period is

non performance based grants years vesting period discretionary

Vesting of restricted stock - At least one Vesting period is

performance based grants year vesting period discretionary

The Amended Plan request represents 3.57% of the Company's fully diluted voting shares.

The decision to adjourn the Annual Meeting and consider the Amended 2008 Plan at the reconvened Annual Meeting was made after the Company reported that a preliminary tally of the votes for the 2008 Plan indicated that the plan as originally proposed would not receive sufficient votes to be approved.

The reconvened Annual Meeting will be held at the Company's headquarters, 1110 Spring Street, Silver Spring, Maryland 20910, at 9:00 a.m. Eastern Time for the following purposes:

1. Approval of the Amended 2008 Plan; and

2. To consider and act upon such other business as may properly come

before the reconvened Annual Meeting.

Only holders of record of the Company's common stock at the close of business on March 7, 2008, the original record date, remain entitled to vote at the reconvened Annual Meeting.

The Company also announces that it filed with the Securities and Exchange Commission (SEC) today an amendment to its Proxy Statement filed with the SEC on March 7, 2008. The Company will mail the amendment and related information and proxy card to its shareholders of record as of March 7, 2008, on or about May 2, 2008. Shareholders are urged to read the amendment and other relevant documents because they relate to the approval of the Amended 2008 Plan.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. [uthr-g]


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Reports First Quarter 2008 Financial Results
2. United Therapeutics to Announce First Quarter 2008 Financial Results Before Market Open on Thursday, May 1, 2008
3. United BioSource Acquires Leading Publication Planning Software and Services Company
4. Genetic Engineering and Biotechnology News (GEN) Blog: International Students in the United States - A Diminishing Pool of Talent for Biotech?
5. HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO).
6. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
7. Moleac Launches NeuroAid10(TM) in the United States
8. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
9. United BioSource Expands Regulatory Affairs Capabilities
10. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
11. United States Patent Office Grants CryoCors Request for Patent Interference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
Breaking Biology Technology:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):